

Scott C Woller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3603417/scott-c-woller-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73 papers	5,616 citations	27 h-index	74 g-index
83 ext. papers	6,948 ext. citations	6 avg, IF	5.31 L-index

#	Paper	IF	Citations
73	Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort.. <i>BMJ Open</i> , 2022 , 12, e053864	3	
72	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <i>Blood Advances</i> , 2021 ,	7.8	4
71	Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. <i>American Journal of Emergency Medicine</i> , 2021 , 41, 80-83	2.9	1
70	Natural Language Processing Performance for the Identification of Venous Thromboembolism in an Integrated Healthcare System. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 10760296211013108	3.3	3
69	Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: A prospective randomized trial. <i>Journal of Trauma and Acute Care Surgery</i> , 2021 , 90, 787-796	3.3	3
68	Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12560	5.1	1
67	Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021 , 153, 58-64	3	2
66	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, e545-e608	5.3	48
65	Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, 2247-2259	5.3	35
64	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. <i>Blood</i> , 2020 , 135, 1788-1810	2.2	33
63	Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2245-2252	15.4	4
62	Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. <i>Blood Advances</i> , 2020 , 4, 2557-2566	7.8	7
61	Diagnostic yield of pulmonary embolism testing in patients presenting to the emergency department with syncope. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 263-268	5.1	3
60	THROMBOEMBOLISM-RISK-BASED ALGORITHM DECREASES ANTICOAGULATION RATES AND BLEEDING RISK AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 2020 , 104, S480-S481	1.8	
59	Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 9-12	5.1	12
58	Timing of parenteral anticoagulation after thrombolysis for the treatment of pulmonary embolism. <i>Thrombosis Research</i> , 2020 , 195, 58-61	8.2	
57	Predicting postdischarge hospital-associated venous thromboembolism among medical patients using a validated mortality risk score derived from common biomarkers. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 872-878	5.1	1

56	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27
55	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2126-2137	15.4	30
54	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 834-842	27.4	5
53	Saving the brain from catheter ablation of atrial fibrillation: the role of pre- and peri-procedural anticoagulation. <i>European Heart Journal</i> , 2019 , 40, 1538-1540	9.5	1
52	Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM-DVT): Methods of a prospective single-arm management study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 340-348	5.1	12
51	Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study. <i>Clinical Cardiology</i> , 2019 , 42, 506-512	3.3	10
50	Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization: The Low-Risk Pulmonary Embolism Prospective Management Study. <i>Chest</i> , 2018 , 154, 249-256	5.3	38
49	Weight-based enoxaparin dosing and deep vein thrombosis in hospitalized trauma patients: A double-blind, randomized, pilot study. <i>Surgery</i> , 2018 ,	3.6	8
48	Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 192	3.3	30
47	Electronic alerts, comparative practitioner metrics, and education improve thromboprophylaxis and reduce venous thrombosis in community hospitals. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018 , 2, 481-489	5.1	9
46	Age-adjusted versus clinical probability-adjusted D-dimer to exclude pulmonary embolism. <i>Thrombosis Research</i> , 2018 , 167, 15-19	8.2	10
45	Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism: Are Guidelines Followed?. <i>Chest</i> , 2018 , 153, 1153-1159	5.3	2
44	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 209S-216S	3.3	2
43	Comparative thrombosis risk of vascular access devices among critically ill medical patients. <i>Thrombosis Research</i> , 2018 , 172, 54-60	8.2	10
42	Atrial fibrillation incrementally increases dementia risk across all CHADS and CHADSVASc strata in patients receiving long-term warfarin. <i>American Heart Journal</i> , 2017 , 188, 93-98	4.9	37
41	The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017 , 120, 75-82	3	4
40	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1115-1124	27.4	142
39	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report 2017 , 317-338		16

38	Venous Thromboembolism in Critically Ill Medical Patients Receiving Chemoprophylaxis: A Focus on Obesity and Other Risk Factors. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 265-73	3.3	12
37	Use of signals and systems engineering to improve the safety of warfarin initiation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 529-33	5.1	
36	Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 239-47	3.3	66
35	Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 154-64	5.1	158
34	Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016 , 10, 231-41	3.4	0
33	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2016 , 149, 315-352	5.3	3090
32	The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) initiative: A summary and review of peripherally inserted central catheter and venous catheter appropriate use. <i>Journal of Hospital Medicine</i> , 2016 , 11, 306-10	2.7	28
31	Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016 , 118, 210-4	3	92
30	Follow-up of Incidental Pulmonary Nodules and the Radiology Report. <i>Journal of the American College of Radiology</i> , 2016 , 13, R18-24	3.5	20
29	Electronic Alerts, Comparative Practitioner Metrics, and Education Improves Thromboprophylaxis and Reduces Thrombosis. <i>American Journal of Medicine</i> , 2016 , 129, 1124.e17-26	2.4	12
28	Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	33
27	Computerized clinical decision support improves warfarin management and decreases recurrent venous thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015 , 21, 197-203	3.3	12
26	The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method. <i>Annals of Internal Medicine</i> , 2015 , 163, S1-40	8	288
25	Antithrombotic therapy in patients with acute coronary syndrome in the intermountain heart collaborative study. <i>Cardiology Research and Practice</i> , 2015 , 2015, 270508	1.9	3
24	Percent Time With a Supratherapeutic INR in Atrial Fibrillation Patients Also Using an Antiplatelet Agent Is Associated With Long-Term Risk of Dementia. <i>Journal of Cardiovascular Electrophysiology</i> , 2015 , 26, 1180-1186	2.7	29
23	Ultrasound of the Whole Arm to Manage Suspected Upper-Extremity Deep Venous Thrombosis. <i>JAMA Internal Medicine</i> , 2015 , 175, 1227-9	11.5	
22	The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities. <i>American Journal of Medicine</i> , 2015 , 128, 986-93.e1	2.4	67
21	Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. <i>Heart Rhythm</i> , 2014 , 11, 2206-13	6.7	101

20	Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014 , 20, 665-72	3.3	27
19	Assessment of the safety and efficiency of using an age-adjusted D-dimer threshold to exclude suspected pulmonary embolism. <i>Chest</i> , 2014 , 146, 1444-1451	5.3	26
18	Follow-up of incidental pulmonary nodules and the radiology report. <i>Journal of the American College of Radiology</i> , 2014 , 11, 378-83	3.5	55
17	Intermittent pneumatic compression in patients with stroke. <i>Lancet, The</i> , 2013 , 382, 484-6	4.0	4
16	Adherence to PIOPED II investigators' recommendations for computed tomography pulmonary angiography. <i>American Journal of Medicine</i> , 2013 , 126, 36-42	2.4	55
15	Withholding anticoagulation following a single negative whole-leg ultrasound in patients at high pretest probability for deep vein thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013 , 19, 79-85	3.3	6
14	Reduction of peripherally inserted central catheter-associated DVT. <i>Chest</i> , 2013 , 143, 627-633	5.3	77
13	Radiation and chest CT scan examinations: what do we know?. <i>Chest</i> , 2012 , 142, 750-760	5.3	80
12	Diagnosis and management of upper extremity deep-vein thrombosis in adults. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1097-108	7	91
11	A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). <i>Circulation</i> , 2012 , 125, 1997-2005	16.7	193
10	Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. <i>American Journal of Medicine</i> , 2011 , 124, 947-954.e2	2.4	81
9	Treatment of chronic lead toxicity with succimer: a case series of 2 adults with retained lead shotgun fragments. <i>American Journal of Forensic Medicine and Pathology</i> , 2011 , 32, 236-8	1	2
8	Atypical calciphylaxis in a patient receiving warfarin then resolving with cessation of warfarin and application of hyperbaric oxygen therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010 , 16, 345-50	3.3	22
7	Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 438-45	27.4	124
6	Risk of symptomatic DVT associated with peripherally inserted central catheters. <i>Chest</i> , 2010 , 138, 803-10	3.3	185
5	Computer surveillance of patients at high risk for and with venous thromboembolism 2010 , 2010, 217-21	1.7	15
4	Safety of Excluding Suspected Deep Vein Thrombosis with a Single Whole-Leg Compression Ultrasound: Systematic Review and Meta-Analysis.. <i>Blood</i> , 2009 , 114, 243-243	2.2	1
3	Hepatic epithelioid hemangioendothelioma presenting as liver infarction. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, xx	6.9	3

2 The use of a fixed high sensitivity to evaluate five D-dimer assaysAbility to rule out deep venous thrombosis: a novel approach. *British Journal of Haematology*, **2005**, 131, 341-7 4.5 5

1 Upper Extremity Thrombosis192-204